 |
Finsbury is handling Takeda Pharmaceuticals' fifth bid for rare drug specialist Shire PLC of Dublin.
If successful, the sweetened $60B cash/stock offer would mark the largest-ever Japanese acquisition of a western firm and propel Takeda into the top-ranks of global drug companies.
Takeda notes the improved bid represents a 58 percent premium over the closing price of Shire shares on March 23, the day before rumors surfaced about a takeover bid.
It said that completion of the deal would give Shire shareholders "a very meaningful stake in a leading global biopharmaceutical company" and benefits from the synergies flowing from the deal.
Shire is considering Takeda's latest bid.
Finsbury's London team of James Murgatroyd Rollo Head and Anjali Unnikrishnan are working the Takeda bid with Kal Goldberg and Chris Ryall in New York.
To negotiate the demands of media, investors, regulators and the market, communicators to make sure that their narrative they construct is defensible every stop of the way.
In a health landscape crowded with claims, brands earn trust by pairing credible proof with human stories, cultural relevance, and empowerment.
Binaytara, the Bellevue, WA-based nonprofit dedicated to improving access to cancer care and fostering scientific research, has appointed FINN Partners as its global PR firm.
Jeffrey Sturchio is joining Finn Partners’ health policy and impact group as senior advisor to counsel clients on the issues shaping global health and innovation access.
A breakthrough is not successful merely because it works. It succeeds when people and health systems can actually use it.
